NTBL vs. SLRX, CNSP, DRMA, CMND, CYCC, QLGN, CYTO, LSDI, BPTH, and GLMD
Should you be buying Notable Labs stock or one of its competitors? The main competitors of Notable Labs include Salarius Pharmaceuticals (SLRX), CNS Pharmaceuticals (CNSP), Dermata Therapeutics (DRMA), Clearmind Medicine (CMND), Cyclacel Pharmaceuticals (CYCC), Qualigen Therapeutics (QLGN), Altamira Therapeutics (CYTO), Lucy Scientific Discovery (LSDI), Bio-Path (BPTH), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical preparations" industry.
Salarius Pharmaceuticals (NASDAQ:SLRX) and Notable Labs (NASDAQ:NTBL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
In the previous week, Salarius Pharmaceuticals and Salarius Pharmaceuticals both had 1 articles in the media. Notable Labs' average media sentiment score of 1.00 equaled Salarius Pharmaceuticals'average media sentiment score.
Notable Labs has lower revenue, but higher earnings than Salarius Pharmaceuticals. Notable Labs is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Notable Labs has a consensus price target of $8.00, indicating a potential upside of 729.02%. Given Salarius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Notable Labs is more favorable than Salarius Pharmaceuticals.
Salarius Pharmaceuticals' return on equity of -62.07% beat Notable Labs' return on equity.
11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 70.5% of Notable Labs shares are held by institutional investors. 3.5% of Salarius Pharmaceuticals shares are held by company insiders. Comparatively, 1.2% of Notable Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Salarius Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Notable Labs has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Salarius Pharmaceuticals received 21 more outperform votes than Notable Labs when rated by MarketBeat users. However, 100.00% of users gave Notable Labs an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote.
Summary
Notable Labs beats Salarius Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Notable Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTBL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTBL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Notable Labs Competitors List
Related Companies and Tools
